Inhibition of colorectal cancer targets IL-6, CTLA-4, & B7-2 by Tislelizumab: molecular docking, dynamics, & STRING protein-protein network analysis

Inhibition of colorectal cancer targets IL-6, CTLA-4, & B7-2 by Tislelizumab: molecular docking, dynamics, & STRING protein-protein network analysis

As a DNA mismatch repair deficit (dMMR) anticancer medication, and a humanized monoclonal antibody (hmAb), Tislelizumab has attracted significant interest in recent years. The programmed cell death protein-1 (PD-1) and its ligands (PD-L1/CD274/B7-H1 and PDL2/CD273) may bind to each other with great...

Full description

Bibliographic Details
Main Authors: Mahmoud Elkazzaz, Shahid Ullah, Tianshun Gao, Israa M. Shamkh, Amr Ahmed, Ted X. Wu, Maii S. Elsharayidi, Mohammad Shahbaz Khan, Aziz-ur Rehman, Marwa M. Lotfy, Abdullah Haikal, Mahmoud Abdalrahman
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Informatics in Medicine Unlocked
Subjects:
Tislelizumab
Dostarlimab
IL-6
B7-2
CTLA-4
Colorectal Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2352914823001697

Internet

http://www.sciencedirect.com/science/article/pii/S2352914823001697

Similar Items